B · Normal
[Yifang Biology: Nomelcitinib (D-2570)’s phase III clinical study for the treatment of moderate to severe plaque psoriasis reached the primary endpoint] On November 1, Yifang Biology (688382.SH) announced that the company’s independently developed TYK2-targeting The registrational phase III clinical study of nomelcitinib (D-2570), a new oral selective inhibitor of JH2, for the treatment of moderate to severe plaque psoriasis has reached the primary endpoint and key secondary endpoints. The results of this study mark a milestone in the clinical development of nomelcitinib (D-2570) in the field of psoriasis.
A-share announcement express 🕐 2026-11-01 15:47
#A-share announcement express
Save as Image Generate a beautiful long image to share on Moments or in group chats Generate now ⬇
← Back to Telegraph

Related telegraphs

[Hengtong Optoelectronics: Chairman proposes to repurchase shares of 100 million 11-01 17:25 [Hongxin Electronics: Chairman proposes to repurchase shares of 200 million to 4 11-01 16:14 [SAIC Group: Vehicle sales in October were 430,000 units, a year-on-year decreas 11-01 16:13 [Great Wall Motors: Car sales in October were 120,400 units, a year-on-year decr 11-01 15:54 [Nearshore Protein: AI-enabled high-throughput wet experiments and data package 11-01 15:52 [Ocean King: AI+ smart lighting-related business revenue scale is limited] On No 11-01 15:49

Comments

0/500
Captcha (click to refresh)
No comments yet